RESUMO
BACKGROUND: In the palliative treatment of patients with advanced, inoperable rectal cancer, combined endoscopic laser and radiotherapy have been claimed to be more effective than laser therapy alone. The number of laser treatments, laser energy used, relapse rate, treatment of relapse, morbidity and survival in consecutive patients who were treated either by laser therapy alone or laser plus radiotherapy was compared. METHODS: Prospective data were analysed with regard to number of treatments, laser energy used, relapse rate, morbidity and survival for 56 consecutive patients. RESULTS: The crude relapse rate was significantly higher in the laser only group than in the laser plus radiotherapy group (58 and 15%, respectively; P = 0.002). There was no difference between the groups in the median total number of laser treatments or the mean total laser energy used. In patients experiencing a relapse, there was no difference in the median number of relapses, the number of laser treatments post-relapse or the total energy used post-relapse. Survival did not differ between the groups and there were no treatment-related deaths. CONCLUSIONS: These findings demonstrate a clear reduction in relapse after using combined laser and radiotherapy to palliate patients with advanced rectal cancer with no appreciable additional morbidity and have encouraged continuing use of this treatment.
Assuntos
Terapia com Luz de Baixa Intensidade , Recidiva Local de Neoplasia/prevenção & controle , Cuidados Paliativos , Proctoscopia , Neoplasias Retais/radioterapia , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Estudos Prospectivos , Neoplasias Retais/complicações , Neoplasias Retais/mortalidade , Taxa de SobrevidaRESUMO
BACKGROUND AND PURPOSE: One aspect of good radiotherapeutic practice is to achieve dose homogeneity. Dose inhomogeneities occur with breast tangent irradiation, particularly in women with large breasts. MATERIALS AND METHODS: Ten Australian radiation oncology centres agreed to participate in this multicentre phantom dosimetry study. An Alderson radiation therapy anthropomorphic phantom with attachable breasts of two different cup sizes (B and DD) was used. The entire phantom was capable of having thermoluminescent dosimeters (TLD) material inserted at various locations. Nine TLD positions were distributed throughout the left breast phantom including the superior and inferior planes. The ten centres were asked to simulate, plan and treat (with a prescription of 100 cGy) the breast phantoms according to their standard practice. Point doses from resultant computer plans were calculated for each TLD position. Measured and calculated (planning computer) doses were compared. RESULTS: The dose planning predictability between departments did not appear to be significantly different for both the small and large breast phantoms. The median dose deviation (calculated dose minus measured dose) for all centres ranged from 2. 3 to 5.3 cGy on the central axis and from 2.1 to 7.5 cGy for the off-axis planes. The highest absolute dose was measured in the inferior plane of the large breast (128.7 cGy). The greatest dose inhomogeneity occurred in the small breast phantom volume (median range 93.2-105 cGy) compared with the large breast phantom volume (median range, 100.1-107.7 cGy). There was considerable variation in the use (or not) of wedges to obtain optimized dosimetry. No department used 3D compensators. CONCLUSION: The results highlight areas of potential improvement in the delivery of breast tangent radiotherapy. Despite reasonable dose predictability, the greatest dose deviation and highest measured doses occurred in the inferior aspects of both the small and large breast phantoms.
Assuntos
Neoplasias da Mama/radioterapia , Relação Dose-Resposta à Radiação , Feminino , Humanos , Imagens de Fantasmas , Lesões por Radiação/prevenção & controle , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeAssuntos
Carcinoma/radioterapia , Neoplasias da Próstata/radioterapia , Braquiterapia/métodos , Carcinoma/patologia , Humanos , Masculino , Estadiamento de Neoplasias , Neoplasias da Próstata/patologia , Lesões por Radiação/prevenção & controle , Dosagem Radioterapêutica , Radioterapia Assistida por Computador , Radioterapia ConformacionalRESUMO
BACKGROUND: Laser and formalin therapy have recently been shown to be safe methods of haemostasis in patients with chronic radiation-induced rectal bleeding (CRRB). The effectiveness of this treatment in terms of improved quality of life remains to be determined. The aim of this study was to develop a questionnaire measure of self-perceived quality of life in patients with CRRB. METHODS: A self-completed Rectal Bleeding Quality of Life Scale (RBQOLS) based on the social and emotional problems experienced by patients with CRRB was developed using standard psychometric methods. Before laser and formalin therapy, 34 consecutive patients completed the questionnaire which was repeated 1 month after treatment and again 5 months later. The validity of the scale was assessed in relation to patient response to treatment. RESULTS: The RBQOLS had high reliability (alpha=0.89) and its concurrent validity was confirmed by a significant association with the pretreatment severity of CRRB assessed endoscopically. The mean RBQOLS score increased from 102 (95 per cent confidence interval 90-114) before treatment to 126 (111-141) after treatment (t=3.1, 33 d.f., P=0.004) and 136 (122-151) at follow-up attesting to its predictive validity. CONCLUSION: The RBQOLS is a reliable and valid device for assessing quality of life of patients with this uncommon, previously intractable and potentially life threatening complication of radiotherapy.
Assuntos
Hemorragia Gastrointestinal/etiologia , Qualidade de Vida , Lesões por Radiação/complicações , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Depressão/etiologia , Feminino , Formaldeído/uso terapêutico , Hemorragia Gastrointestinal/psicologia , Hemorragia Gastrointestinal/terapia , Humanos , Terapia a Laser , Fotocoagulação/métodos , Masculino , Pessoa de Meia-Idade , Neoplasias da Próstata/radioterapia , Reto , Inquéritos e Questionários , Telangiectasia/etiologia , Telangiectasia/terapia , Neoplasias da Bexiga Urinária/radioterapia , Neoplasias do Colo do Útero/radioterapiaRESUMO
BACKGROUND: Development of bone marrow support techniques has altered the standard chemotherapeutic management of haematological malignancies, and these techniques are now being increasingly utilized in solid tumours. In breast cancer, survival benefits have resulted from conventional dose adjuvant chemotherapy, but outcomes remain poor in many women with high-risk disease. Improved response rates with high-dose chemotherapy (HDC) in metastatic disease have led to the investigation of these techniques in adjuvant therapy of high-risk localized disease. In some high-risk patient subgroups survival is extremely poor, with 5-year rates below 30%. Improved adjuvant strategies for patients in these subgroups are therefore urgently required. In Australasia, oncology departments are currently considering accrual of women with high-risk disease into the International Breast Cancer Study Group (IBCSG) 15-95 Trial investigating HDC/stem cell transplantation. METHODS: The present paper reviews the available data on the efficacies and toxicities of currently available high-dose chemotherapeutic strategies; discussing methodological considerations relevant to their introduction and safe use in the adjuvant setting in Australia and New Zealand. RESULTS: Although response rates with HDC in metastatic disease are encouraging, the clinical effectiveness of current HDC regimens in adjuvant management has not been established and is limited by significant toxicity. CONCLUSIONS: The introduction of HDC strategies for high-risk breast cancer in Australia encounters difficulties both in trial design and potential clinical practice.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Austrália , Neoplasias da Mama/radioterapia , Neoplasias da Mama/terapia , Quimioterapia Adjuvante/métodos , Ensaios Clínicos como Assunto , Ciclofosfamida/administração & dosagem , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Transplante de Células-Tronco Hematopoéticas , Humanos , Metotrexato/administração & dosagem , Gestão de RiscosRESUMO
UNLABELLED: BACKGROUNDS AND METHODS: This study reviews the clinical features and reports the preliminary results of treatment of 34 consecutive patients with clinically significant bleeding from chronic, radiation-induced proctitis, using a combination of endoscopic YAG Laser and the application of topical formalin dressings to the rectal mucosa. RESULTS: Bleeding ceased in 25 patients (74%); bleeding continued but occurred only slightly and occasionally in five patients (15%); and three patients required operation to control the bleeding (9%). One patient relapsed after treatment and died while receiving a further transfusion. CONCLUSIONS: This experience has been used to develop a management protocol for patients with this serious complication.
Assuntos
Hemorragia Gastrointestinal/cirurgia , Proctite/cirurgia , Lesões por Radiação/cirurgia , Administração Tópica , Idoso , Distribuição de Qui-Quadrado , Doença Crônica , Protocolos Clínicos , Colonoscopia/métodos , Intervalos de Confiança , Feminino , Seguimentos , Formaldeído/administração & dosagem , Hemoglobinas/análise , Humanos , Fotocoagulação a Laser/efeitos adversos , Masculino , Pessoa de Meia-Idade , Telangiectasia/cirurgia , Resultado do Tratamento , Neoplasias Urogenitais/radioterapiaRESUMO
OBJECTIVE: To collect data on the operation of two private radiation oncology practices which operate linear accelerators in order to compare their patterns of practice with that of the practice of a public teaching hospital radiation oncology department. METHOD: Retrospective review of practice records and collection of data on the utilisation of the respective radiation oncology practices. RESULTS: Patient data was analysed to provide a "summarised" profile of treatment of the major cancers, by primary site, for each practice. Problems were encountered in adapting existing records at the various centres in order to obtain compatible data for comparison. The study demonstrated the need for adequate and consistent data to be collected by Australian radiation oncology facilities so that valid comparisons of practice patterns can be undertaken.
Assuntos
Oncologia/normas , Neoplasias/radioterapia , Padrões de Prática Médica , Prática Privada/normas , Adolescente , Adulto , Idoso , Austrália , Institutos de Câncer/estatística & dados numéricos , Coleta de Dados , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Serviço Hospitalar de Medicina Nuclear/estatística & dados numéricos , Estudos Retrospectivos , Revisão da Utilização de Recursos de Saúde/estatística & dados numéricosRESUMO
Allogeneic bone marrow transplantation using HLA-identical sibling donors was performed in 29 patients with malignant blood diseases and in four patients with severe aplastic anaemia. Twenty-five patients received immunosuppressive therapy with cyclosporin A to minimize graft-versus-host disease (GVHD) and eight received methotrexate. Twenty-one of 29 patients (72%) with malignant blood diseases and three of the four patients with severe aplastic anaemia remained alive and disease-free from 0.5 to 16 (median, seven) months after transplantation. Acute GVHD, predominantly of the skin, occurred in 25 of 28 evaluable cyclosporin A recipients (of whom two died), and in all five evaluable methotrexate recipients. Mild chronic GVHD occurred in 10 of 16 evaluable patients. Interstitial pneumonitis occurred in five patients, of whom two died. HLA-identical sibling marrow transplantation is associated with a mortality similar to that of induction chemotherapy for acute leukaemia, and should be considered in adults with acute leukaemia in remission or relapse, chronic myelogenous leukaemia in metamorphosis or blastic transformation, lymphoma unresponsive to conventional therapy, and in severe aplastic anaemia.